Table 1 Patient demographics
From: Upregulation of SLC2A3 gene and prognosis in colorectal carcinoma: analysis of TCGA data
Discovery Set (TCGA, N = 345) | Validation Set (GSE39582, N = 501) | |
|---|---|---|
Age, yr | ||
Median | 67 | 68.1 |
Interquartile range | (55–75) | (59–76) |
Sex | ||
Female | 157 (46%) | 229 (46%) |
Male | 188 (54%) | 272 (54%) |
AJCC TNM Stage | ||
I | 54 (16%) | 31 (6%) |
II | 130 (38%) | 244 (49%) |
III | 111 (32%) | 166 (33%) |
IV | 50 (14%) | 60 (12%) |
Microsatellite instability | ||
MSI-L and MSS | 291 (84%) | |
MSI-H | 54 (16%) | |
BRAF status | ||
V600E | 50 (14%) | 49 (10%) |
Wild-type | 295 (86%) | 452 (90%) |
KRAS status | ||
Mutant | 144 (42%) | 198 (40%) |
Wild-type | 201 (58%) | 303 (60%) |
OS event | ||
Event | 78 (23%) | 171 (34%) |
Non-event | 267 (77%) | 330 (66%) |
OS months | ||
Median | 31.4 | 56.5 |
Range | (0–147.9) | (0–201) |
DFS event | ||
Event | 83 (24%) | 150 (30%) |
Non-event | 222 (64%) | 346 (69%) |
Not available | 40 (12%) | 5 (1%) |
DFS months | ||
Median | 21 | 44 |
Range | (0–148) | (0–201) |